Emergency / crisis support: /emergency
CANSA Toll-Free: 0800 22 6622
If you are facing a declined claim, an exhausted oncology sub-limit, or a bill you cannot pay — this guide covers the specific steps to take now.
The Most Common Prostate Cancer Medical Aid Crises
1. Novel hormonal agent declined (abiraterone/enzalutamide) Your oncologist has recommended a second-line hormonal agent for mCRPC; your scheme has declined the exceptional-needs application.
2. Oncology sub-limit exhausted Your scheme has paid to its annual oncology cap; it is refusing further treatment costs.
3. Robotic surgery shortfall You had robotic prostatectomy; your scheme funded only the open-surgery equivalent; the balance is outstanding.
4. ADT funded as non-PMB Your scheme is processing GnRH agonist injections incorrectly as non-PMB items, or refusing ADT because it considers it a chronic (non-oncology) benefit.
5. Pre-authorisation declined or not obtained A procedure or imaging study was not pre-authorised and the claim was rejected in full.
Each situation has a clear escalation path. Do not stop treatment. The legal framework is on your side for PMB-classified treatment — but you must engage actively with the process.
If Abiraterone or Enzalutamide Was Declined
ADT (GnRH agonists) is the PMB minimum treatment standard for metastatic prostate cancer. Novel hormonal agents (abiraterone, enzalutamide) are typically exceptional-needs. If your scheme has declined:
Step 1: Request the decline in writing with specific clinical rationale. Verbal declines are insufficient — you need the written reasons to appeal.
Step 2: Ask your oncologist to upgrade the motivation. Include: PSA doubling time, bone scan results, prior treatment history, ISUP grade, published data on abiraterone/enzalutamide survival benefit in mCRPC (LATITUDE, ENZAMET, and ARCHES trials are well-established references). The stronger the clinical evidence package, the higher the approval probability on resubmission.
Step 3: Request a peer-to-peer clinical review — your oncologist speaks directly with the scheme's medical advisor. This resolves a significant proportion of exceptional-needs disputes without requiring a formal appeal.
Step 4: If still declined, submit a formal internal appeal to the scheme's appeals committee (most schemes have a 30-day response SLA under their scheme rules).
Step 5: If the internal appeal fails, file a complaint with the Council for Medical Schemes (CMS): 0861 123 267 or www.medicalschemes.org.za. CMS adjudication is free and legally binding on schemes.
If Your Oncology Sub-Limit Is Exhausted
Determine whether ongoing treatment is PMB-classified. ADT is PMB. Standard chemotherapy (docetaxel) is PMB. Oncology sub-limits apply to non-PMB oncology benefits. If your continuing treatment is PMB-classified, the scheme's annual oncology cap does not override their PMB obligation.
Write to your scheme's case management team: state clearly that you are receiving PMB-minimum oncology treatment, name the specific treatment, and request confirmation that it will continue to be funded. Your oncologist must confirm in writing that the treatment constitutes the PMB minimum treatment standard for metastatic prostate cancer.
If the scheme disputes the PMB classification, escalate to the CMS. PMB disputes in oncology are a well-established escalation pathway and the CMS has consistently found in favour of patients where the treatment is genuinely the PMB minimum standard.
If You Have an Outstanding Robotic Prostatectomy Bill
If your scheme funded open-surgery rates and you chose robotic-assisted: - If the scheme advised you before surgery that only open rates would be funded and you chose robotic anyway, the shortfall is your responsibility. - If the scheme did NOT advise you prior to surgery that only open rates would be funded, you have grounds to dispute the claim. Submit a formal dispute with your scheme, noting the failure to disclose the limitation in advance.
Contact the hospital billing department and the urologist's practice manager. Request itemised invoices for both the hospital and professional components. Many urologists will negotiate a payment plan on the shortfall portion when the alternative is a payment dispute.
If ADT Is Being Processed as Non-PMB
GnRH agonist therapy (leuprolide, triptorelin) for metastatic or locally advanced prostate cancer is the PMB-minimum treatment standard. If your scheme is classifying these injections as a chronic (non-oncology) benefit, or is applying a chronic benefit co-payment, this is incorrect.
Write to case management citing PMB regulations and requesting that ADT be reclassified and processed as PMB oncology treatment at 100% benefit with no co-payment. Include your urologist's staging documentation confirming metastatic or locally advanced disease.
Outstanding Bills: Triage Guide
| Situation | Priority | Action |
|---|---|---|
| ADT (GnRH agonist) processed as non-PMB | Urgent | Write to case management; cite PMB regulations |
| Sub-limit hit on PMB-classified treatment | Urgent | Written PMB letter + oncologist confirmation |
| Exceptional-needs declined (abiraterone/enzalutamide) | High | Written appeal + peer-to-peer review + CMS if needed |
| Robotic surgery shortfall | Medium | Dispute if not advised prior; payment plan otherwise |
| Gap OPL (R220,000) exhausted | Informational | No further gap payment; remaining shortfalls are out-of-pocket |
| Pre-authorisation not obtained | Varies | Submit retrospective authorisation request with clinical motivation |
What the Law Guarantees You
Under the Medical Schemes Act and PMB regulations: - PMB-classified treatment must be funded regardless of sub-limits or formulary restrictions. - You have the right to written reasons for any claim decline, and the scheme must provide these. - You have the right to a formal internal appeal process. - You have the right to CMS adjudication at no cost to you. - The CMS's decisions are binding on schemes.
Escalation Contacts
Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.org.za CANSA Patient Rights: 0800 22 6622 (toll-free) ProstateSA: www.prostatesa.org AURA Emergency: /emergency
Talk to Eldon
Get urgent help with your cover situation →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).